cas 916420-27-4|| where to buy tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

製品名:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

IUPAC Name:tert-butyl 2,4-dichloro-5H,6H,7H,8H-pyrido[3,4-d]pyrimidine-7-carboxylate

包装単位	有効在庫	価格（USD）
CM104183-5g	in stock	Ľŉ
CM104183-10g	in stock	ǤƓǤ
CM104183-25g	in stock	ǵǊǵ
CM104183-100g	in stock	ƄȎŢ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 916420-27-4 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:916420-27-4; 分子式:C12H15Cl2N3O2; 融点:-; SMILESコード:CC(C)(C)OC(=O)N1CCC2=C(Cl)N=C(Cl)N=C2C1; 密度:

: カタログ番号:CM104183; 分子量:304.17; 沸点:; MDL番号:MFCD09025732; 保管方法:

: Adagrasib; Jan. 10, 2024, EC approves KRAZATI (adagrasib) as a targeted treatment option for patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.
Adagrasib is an orally available, potent, irreversible, small molecule inhibitor of KRAS G12C mutant isoform for the treatment of solid tumours harbouring KRAS G12C oncogenic driver mutation. Adagrasib covalently binds to the mutant cysteine in KRAS G12C and locks the mutant KRAS protein in its inactive state, thereby preventing downstream signalling without affecting wild-type KRAS protein.